Search results for "Ligo"

showing 10 items of 1427 documents

The humoral immune system has a key prognostic impact in node-negative breast cancer.

2008

Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with…

OncologyAdultCancer Researchmedicine.medical_specialtyMultivariate analysisEstrogen receptorBreast NeoplasmsMetastasisCohort StudiesBreast cancerImmune systemInternal medicineMedicineCluster AnalysisHumansAgedCell ProliferationOligonucleotide Array Sequence AnalysisAged 80 and overbusiness.industryProportional hazards modelGene Expression ProfilingHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticOncologyNeutrophil InfiltrationLymphatic MetastasisCohortImmunologyAntibody FormationFemaleLymph NodesbusinessGenes NeoplasmCancer research
researchProduct

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

2008

OncologyCancer Researchmedicine.medical_specialtyCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Text miningInternal medicineProto-Oncogene ProteinsmedicineCluster AnalysisHumansColorectal TumorsNeoplasm StagingOligonucleotide Array Sequence AnalysisCetuximabbusiness.industryGene Expression ProfilingPatient SelectionAntibodies MonoclonalSignature (logic)ErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeOncologyMutationras ProteinsbusinessColorectal NeoplasmsKras mutationmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

High-dose radiotherapy for oligo-progressive NSCLC receiving EGFR tyrosine kinase inhibitors: Real world data

2020

Background/aim Local ablative treatments for oligo-progressive, EGFR mutated non-small cell lung cancer (mut-NCSLC) may improve long-term disease control and survival. We analyzed the efficacy of hypo-fractionated, high-dose radiation therapy (HDRT), in association with prolonged EGFR tyrosine kinase inhibitors (TKI) in oligo-progressive, EGFR mutant-NSCLC. Patients and methods Progression-free survival-1 (PFS-1, date from initiation of TKI therapy until oligo-progression or death), and progression-free survival-2 (PFS-2, date of focal progression until further progression or death) were evaluated. Results Thirty-six patients were analyzed. The median PFS 1 was 12.5 months. HDHRT consisted …

OncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentEGFR high-dose radiotherapy Non-small cell lung cancer oligo-progressionEGFRGeneral Biochemistry Genetics and Molecular Biologyoligo-progression03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicinemedicineOverall survivalHumansProtein Kinase InhibitorsRetrospective StudiesPharmacologybusiness.industryEGFR Non-small cell lung cancer high-dose radiotherapy oligo-progressionEGFR; High-dose radiotherapy; Non-small cell lung cancer; Oligo-progressionEGFR Tyrosine Kinase Inhibitorshigh-dose radiotherapyDisease controlProgression-Free SurvivalErbB ReceptorsRadiation therapy030220 oncology & carcinogenesisMutationNon small cellbusinessReal world dataResearch Article
researchProduct

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

2021

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety. 211 patients were registered by 90 German centres. Data were collected retrospectively by questionnaire and queries. 56 centres reported data on 126 patients who actually received at least one cycle of durvalumab. In contrast to the PACIFIC-trial population, some patients with oligometastatic disease and a history of autoimmune disease are included in the EAP population. Information o…

OncologyPD-L1medicine.medical_specialtyDurvalumabSurvivalmedicine.medical_treatmentPopulationLocally advancedlcsh:Computer applications to medicine. Medical informaticsNSCLC03 medical and health sciencesOligometastatic0302 clinical medicineInternal medicineCheckpoint inhibitormedicineStage (cooking)lcsh:Science (General)Lung cancereducationAdverse effect030304 developmental biologyData Article0303 health scienceseducation.field_of_studyChemotherapyMultidisciplinarybusiness.industryReal worldmedicine.diseaselcsh:R858-859.7business030217 neurology & neurosurgeryChemoradiotherapylcsh:Q1-390AutoimmuneData in Brief
researchProduct

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

2013

Estrogen receptor (ER)-negative tumors represent 20-30% of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry. The etiology and clinical behavior of ER-negative tumors are different from those of tumors expressing ER (ER positive), including differences in genetic predisposition. To identify susceptibility loci specific to ER-negative disease, we combined in a metaanalysis 3 genome-wide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of 40 follow-up studies (6,514 cases and 41,455 controls), genotyped using a custom Illumina array, iCOGS, developed by the Collaborative Oncological Gene-environm…

Oncologygenetic associationbody-mass indexEstrogen receptorGenome-wide association studycancer riskBioinformaticssusceptibilitychromosome 1q0302 clinical medicineRisk Factorssingle nucleotide polymorphismGenotypeestrogenCooperative Behaviorcomparative studyOligonucleotide Array Sequence Analysis0303 health scienceschromosome 16q3. Good healthReceptors Estrogenpriority journal030220 oncology & carcinogenesisFemalecancer invasionsignal transductionbreast cancer; cancer invasion; cancer risk; chromosome 1; chromosome 16q; chromosome 1q; chromosome 2p; comparative study; follow up; gene locus; genetic association; genetic susceptibility; human; nucleotide sequence; priority journal; signal transduction; single nucleotide polymorphismmedicine.medical_specialtyGenotypegene locusBreast NeoplasmsSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticle03 medical and health sciencesBreast cancerbreast cancerMeta-Analysis as TopicSDG 3 - Good Health and Well-beingInternal medicineexpressionGeneticsmedicineGenetic predispositionHumansfollow upGenetic Predisposition to Diseasehumanchromosome 1gene030304 developmental biologyCase-control studyCancernucleotide sequencemedicine.diseasechromosome 2pGenetic LociCase-Control Studiescommon variantGenome-Wide Association Studygenetic susceptibilityNature Genetics
researchProduct

Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association…

2013

AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-m…

Oncologymedicine.medical_specialtyProlinePegylated-interferonAlpha interferonHepacivirusPharmacologyAntiviral AgentsTelaprevirTelaprevirPolyethylene GlycolsHCV THERAPYchemistry.chemical_compoundLiver diseaseDrug TherapyPegylated interferonBoceprevirInternal medicineRibavirinmedicineHumansProtease InhibitorsChronicBoceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Gastroenterology; HepatologyBoceprevirDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatologyHepatitis C Chronicmedicine.diseaseHepatitis CCirrhosischemistryCombinationDrug Therapy CombinationbusinessOligopeptidesmedicine.drug
researchProduct

Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma pat…

2021

The lack of a randomized trial comparing carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) prompted us to assess the relative usefulness of one triplet over the other. Five independent retrospective cohorts of 883 relapsed/refractory multiple myeloma (RRMM) patients, including 300 EloRd and 583 KRd cases, outside clinical trials, entered this non-randomized comparison. KRd cohort accounted for a higher incidence of younger patients, cases with ≥3 lines of therapy, already exposed to lenalidomide, International Staging System (ISS) stage III, and abnormal lactic dehydrogenase (LDH) level compared with EloRd cohort. Moreover, cytogenetic risk categori…

Oncologymedicine.medical_specialtySalvage therapyAntibodies Monoclonal HumanizedDexamethasoneSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansElotuzumabLenalidomideDexamethasoneMultiple myelomaLenalidomideRetrospective StudiesSalvage Therapycarfilzomibbusiness.industryHazard ratioHematologyGeneral Medicinemedicine.diseaseCarfilzomibelotuzumabmultiple myelomachemistryCohortbusinessOligopeptidesmedicine.drug
researchProduct

Strategies in Glioma-Surgery

2011

1.1 Epidemiology and classification of gliomas Malignant glioma is one of the most feared diseases in the industrialized nations. About 77% of all malignant tumors within the central nervous system are gliomas. There are about 18.000 newly diagnosed cases annually within the USA (9/100.000 inhabitants per year) and the disease causes about 13.000 deaths each year. Statistically this is a higher loss of life-time than all other tumor-entities together (Schwartzbaum et al., 2006). About 45-50% of these gliomas are histologically classified as gliobalstoma multiforme (GBM) the most aggressive type of glioma which is classified as WHO grade IV (following the classification of Kleihues et al., 2…

Oncologymedicine.medical_specialtybusiness.industryAnaplastic oligodendrogliomaGlioma surgeryNewly diagnosedDiseasemedicine.diseaseWell differentiatednervous system diseasesInternal medicineGliomaEpidemiologymedicinebusinessneoplasmsAnaplastic astrocytoma
researchProduct

One-step reactive processing of low density polyethylene and octavinyl polyhedral oligomeric silsesquioxane

2015

Polyhedral oligomeric silsesquioxane (POSS) are an innovative class of organosilicon compounds suitable for formulation of advanced organic-inorganic hybrid materials. Nanocomposites based POSS found application mostly in high-temperature resistance and fire-resistance materials. POSS are characterized by a three dimensional cage-like structure, made of Si-O bonds, with different organic groups directly linked to the Si atoms of the cage structure. The organic groups can be designed to facilitate the dispersion of the nanoparticle itself in the polymer matrix or also to react with the polymer chain. This work focuses on the possibility to obtain crosslinking of polyethylene using octavinyl-…

One-step reactive processing low density polyethylene octavinyl polyhedral oligomeric silsesquioxane
researchProduct

Transcriptome based identification of mouse cumulus cell markers that predict the developmental competence of their enclosed antral oocytes

2013

BACKGROUND: The cumulus cells (CCs) enveloping antral and ovulated oocytes have been regarded as putative source of non-invasive markers of the oocyte developmental competence. A number of studies have indeed observed a correlation between CCs gene expression, embryo quality, and final pregnancy outcome. Here, we isolated CCs from antral mouse oocytes of known developmental incompetence (NSN-CCs) or competence (SN-CCs) and compared their transcriptomes with the aim of identifying distinct marker transcripts. RESULTS: Global gene expression analysis highlighted that both types of CCs share similar transcriptomes, with the exception of 422 genes, 97.6% of which were down-regulated in NSN-CCs …

OocyteCumulus CellsfungiDevelopmental competenceMicePregnancyOocytesGeneticsAnimalsFemaleFunction and Dysfunction of the Nervous SystemTranscriptomeBiomarkersCell NucleolusResearch ArticleOligonucleotide Array Sequence AnalysisBiotechnologyBMC Genomics
researchProduct